Targeted apoee4 gene therapy for alzheimer's disease treatment
A novel gene therapy targeting APOEe4 expression aims to reduce amyloid-β pathology, decrease neuroinflammation, and slow cognitive decline in Alzheimer's patients without detrimental effects of complete APOE elimination.
Overview
Ascendis Pharma introduces a cutting-edge gene therapy focused on the targeted epigenetic downregulation of APOEε4 expression, the most significant genetic risk factor in late-onset Alzheimer's disease (LOAD). This therapy aims to reduce amyloid-β pathology and neuroinflammation while slowing cognitive decline in patients, particularly those carrying two copies of the APOEe4 allele. Unlike complete APOE elimination, which may be harmful, this approach precisely downregulates APOEe4, offering a promising therapeutic avenue for individualized treatment guided by APOE genotyping and biomarkers.
Technical specifications
Key Features:
- Targeted APOEε4 Downregulation: Focuses on reducing toxic APOEe4 protein levels to mitigate Aβ aggregation and tau phosphorylation.
- Therapeutic Precision: Utilizes CLAIRIgene's epigenome therapy for precise gene expression control.
- Comprehensive Validation: Includes testing in an E4KI/3xTg-AD mouse model, optimizing delivery routes, and conducting safety and bioavailability studies.
- Safety and Efficacy Assessment: Evaluates APOEe4 reduction, improved AD pathology markers, and off-target effects, with a goal of >50% reduction in APOEe4 expression.
- Multiple Delivery Routes: Compares intrathecal and stereotaxic injections for optimal therapeutic delivery.
Technology readiness level
This gene therapy is at Technology Readiness Level 3, indicating it has been demonstrated to reduce APOEe4 expression in vivo and impact Alzheimer's pathology in patient samples. Further validation in animal models and safety studies are ongoing to advance development and therapeutic application.
About Ascendis Pharma
Ascendis Pharma is a global biopharmaceutical company based in Denmark that utilizes its proprietary TransCon technology platform to develop therapies designed to improve safety, efficacy, and patient convenience. The TransCon, or transient conjugation, platform works by masking active molecules and then releasing them in a predictable manner within the body, aiming to create best-in-class product candidates. The company focuses primarily on areas such as endocrinology, including rare diseases like hypoparathyroidism and achondroplasia, as well as oncology, while also maintaining collaborations for other therapeutic areas and markets.
The company’s development pipeline includes marketed products such as YORVIPATH for hypoparathyroidism and SKYTROFA for pediatric growth hormone deficiency. By addressing unmet medical needs through its technology-driven approach, Ascendis Pharma aims to make a meaningful difference for patients, caregivers, and healthcare providers. The company operates globally with research and development facilities in Europe and the United States, managing its clinical programs and market expansions to support its integrated biopharmaceutical business model.
delivered to your inbox.